Vertex Pharmaceuticals is laying off 125 employees and consolidating their Rhode Island buildings after a failed diabetes ...

The stock's fall snapped a three-day winning streak.

According to a Worker Adjustment Retraining Notification written by Vertex to the R.I. Department of Labor and Training, ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a prominent player in the biotechnology industry with a market capitalization of $117 billion, is navigating a pivotal phase in its growth strategy.

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $455.45, denoting a -1% move from the preceding trading day.

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 2.68% on an annualized basis producing an ...

Vertex is trimming its Rhode Island footprint on the back of a scrapped “cells plus device” program in diabetes, leaving 125 ...

The layoffs will heavily affect Vertex’s operations in Rhode Island, where the biotech will consolidate three facilities into ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company ...

Vertex's focus for now is on being less of “a one-franchise organisation” and diversifying its portfolio. The company is investigating new medicines for serious diseases with key unmet needs.

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical ...